These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36851522)

  • 1. Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference.
    Anker SC; Szczeponik MG; Dessila J; Dittus K; Engeland CE; Jäger D; Ungerechts G; Leber MF
    Viruses; 2023 Jan; 15(2):. PubMed ID: 36851522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
    Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
    Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.
    Baertsch MA; Leber MF; Bossow S; Singh M; Engeland CE; Albert J; Grossardt C; Jäger D; von Kalle C; Ungerechts G
    Cancer Gene Ther; 2014 Sep; 21(9):373-80. PubMed ID: 25145311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.
    Xia M; Gonzalez P; Li C; Meng G; Jiang A; Wang H; Gao Q; Debatin KM; Beltinger C; Wei J
    J Virol; 2014 May; 88(9):5152-64. PubMed ID: 24574393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measles virus for cancer therapy.
    Russell SJ; Peng KW
    Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insert Stability and In Vivo Testing of MicroRNA-Detargeted Oncolytic Picornaviruses.
    Schulze AJ
    Methods Mol Biol; 2020; 2058():77-94. PubMed ID: 31486032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.
    Bastin D; Aitken AS; Pelin A; Pikor LA; Crupi MJF; Huh MS; Bourgeois-Daigneault MC; Bell JC; Ilkow CS
    J Immunother Cancer; 2018 Jun; 6(1):62. PubMed ID: 29921327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic measles virus strains as novel anticancer agents.
    Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
    Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering and combining oncolytic measles virus for cancer therapy.
    Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
    Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy.
    Ruiz AJ; Hadac EM; Nace RA; Russell SJ
    J Virol; 2016 Apr; 90(8):4078-4092. PubMed ID: 26865716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.
    Leber MF; Baertsch MA; Anker SC; Henkel L; Singh HM; Bossow S; Engeland CE; Barkley R; Hoyler B; Albert J; Springfeld C; Jäger D; von Kalle C; Ungerechts G
    Mol Ther Oncolytics; 2018 Jun; 9():30-40. PubMed ID: 29988512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities to debottleneck the downstream processing of the oncolytic measles virus.
    Loewe D; Dieken H; Grein TA; Weidner T; Salzig D; Czermak P
    Crit Rev Biotechnol; 2020 Mar; 40(2):247-264. PubMed ID: 31918573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic measles virus strains in the treatment of gliomas.
    Allen C; Paraskevakou G; Liu C; Iankov ID; Msaouel P; Zollman P; Myers R; Peng KW; Russell SJ; Galanis E
    Expert Opin Biol Ther; 2008 Feb; 8(2):213-20. PubMed ID: 18194077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus.
    Allagui F; Achard C; Panterne C; Combredet C; Labarrière N; Dréno B; Elgaaied AB; Pouliquen D; Tangy F; Fonteneau JF; Grégoire M; Boisgerault N
    Curr Gene Ther; 2017; 16(6):419-428. PubMed ID: 28042780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses.
    Lundstrom K
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust envelope exchange platform for oncolytic measles virus.
    Neault S; Bossow S; Achard C; Bell JC; Diallo JS; Leber MF; Ungerechts G
    J Virol Methods; 2022 Apr; 302():114487. PubMed ID: 35104497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.